Kangtai Biological’s trivalent influenza vaccine clinical trial application accepted
May 30, 2025
Source: drugdu
94
On May 28, Kangtai Biological (300601) issued an announcement that it had received an acceptance notice issued by the National Medical Products Administration today, agreeing to accept the clinical trial application for the trivalent influenza virus split vaccine (MDCK cells) jointly developed by the company and Lanzhou Bailing Biotechnology Co., Ltd.
The vaccine is suitable for people aged 3 years and above and is intended to stimulate the body to produce immunity against influenza viruses to prevent influenza caused by related types of influenza viruses.
In the first quarter of 2025, Kangtai Biological achieved revenue of 645 million yuan and net profit attributable to shareholders of the parent company of 22.43 million yuan.
https://finance.eastmoney.com/a/202505283416827087.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- CureVac reaches settlement with BioNTech, Pfizer over COVID-19 vaccine patents August 9, 2025
- New progress in AIDS vaccine research and development! Vaccines may usher in new opportunities August 9, 2025
- Bio-thera receives approval for clinical trials of BAT1308 and other drugs August 9, 2025
- FDA approves Tongxin Medical’s BrioVAD to enter confirmatory clinical study August 9, 2025
- Fosun Pharma’s HLX43 for injection receives approval from the U.S. FDA for clinical trials August 9, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
